Therefore, we hypothesised that altering RIPK4 expression impairs NFκB and Wnt/β-catenin pathways, also known to regulate chemoresistance and recurrence and increase the sensitivity of melanoma cells to CisPt treatment. Here, RIPK4 is linked to melanoma.